Home » FDA Approves Medical Isotope From Australian Reactor
FDA Approves Medical Isotope From Australian Reactor
Molybdenum 99 (Mo-99) produced by the Open Pool Australian Light-water (OPAL) reactor has been approved for use in the U.S., Mary Taylor, vice president of global regulatory affairs for Lantheus Medical Imaging, said. The company received approval from Health Canada last month to use the Australian Mo-99 to generate technetium-99m, a medical isotope commonly used in diagnostic imaging tests. The use of Mo-99 in Canada and the U.S. from the OPAL reactor will be the first commercial quantities of the compound produced by the reactor to be used outside of Australia.
Devices & Diagnostics Letter
Devices & Diagnostics Letter
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct